Breast cancer cell-derived GM-CSF licenses regulatory Th2 induction by plasmacytoid predendritic cells in aggressive disease subtypes

Cancer Research

Volumn 75, Issue 14, 2015, Pages 2775-2787

  Ghirelli, Cristina ^a,b   Reyal, Fabien ^b   Jeanmougin, Marine ^a,b   Zollinger, Raphaël ^a,b   Sirven, Philémon ^a,b   Michea, Paula ^a,b   Caux, Christophe ^c,d,e   Bendriss Vermare, Nathalie ^c,d,e   Donnadieu, Marie Hélène ^a,b   Caly, Martial ^b   Fourchotte, Virginie ^b   Vincent Salomon, Anne ^b   Sigal Zafrani, Brigitte ^b   Sastre Garau, Xavier ^b   Soumelis, Vassili ^a,b,f  

^a PSL RESEARCH UNIVERSITY   (France)

^b INSTITUT CURIE   (France)

^c UNIVERSITÉ LYON 1   (France)

^d CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^e CENTRE LÉON BÉRARD   (France)

^f CBT 507 Centre of Clinical Investigations   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

ARTICLE; BREAST CANCER; CANCER CELL; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL INFILTRATION; CELL MATURATION; CELL SURVIVAL; CELL VIABILITY; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOGENESIS; PLASMACYTOID DENDRITIC CELL; PLASMACYTOID PREDENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH2 CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; BREAST TUMOR; COLON TUMOR; DENDRITIC CELL; DRUG EFFECTS; FEMALE; HT 29 CELL LINE; IMMUNOLOGY; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; REGULATORY T LYMPHOCYTE; TUMOR CELL CULTURE; TUMOR INVASION;

BREAST NEOPLASMS; CELL SURVIVAL; COLONIC NEOPLASMS; DENDRITIC CELLS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HT29 CELLS; HUMANS; MCF-7 CELLS; NEOPLASM INVASIVENESS; T-LYMPHOCYTES, REGULATORY; TH2 CELLS; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 84942376836     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2386     Document Type: Article

References (54)

1. Pardoll D. Does the immune system seetumors as foreign or self? Annu Rev Immunol 2003; 21: 807-39.
2. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7.
3. de Visser K.E., Korets LV, Coussens LM De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005; 7: 411-23.
4. Condeelis J, Pollard JW Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006; 124: 263-6.
5. Mantovani A, Romero P, Palucka A.K., Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008; 371: 771-83.
6. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-99.
7. Moore RJ, Owens DM, Stamp G, Arnott C., Burke F, East N, et al Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 1999; 5: 828-31.
8. Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 2006; 25: 409-16.
9. Menetrier-Caux C., Montmain G, Dieu M.C., Bain C., Favrot MC, Caux C, et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998; 92: 4778-91.
10. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacy-toid dendritic cell precursors. Annu Rev Immunol 2005; 23: 275-306.
11. Kadowaki N, Antonenko S, Lau J.Y., Liu YJ. Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J Exp Med 2000; 192:219-26.
12. Ito T, Yang M, Wang Y.H., Lande R., Gregorio J, Perng OA, et al Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med 2007; 204: 105-15.
13. DeNardo DG, Coussens LM Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007; 9: 212.
14. Ghirelli C, Zollinger R, Soumelis V. Systematic cytokine receptor profiling reveals GM-CSF as a novel TLR-independent activator of human plasma-cytoid predendritic cells. Blood 2010; 115: 5037-40.
15. Grouard G, Rissoan MC, Filgueira L, Durand I., Banchereau J, Liu YJ. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med 1997; 185: 1101-11.
16. Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal Malefyt R, et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999; 283: 1183-6.
17. Wislez M, Fleury-Feith J, Rabbe N., Moreau J, Cesari D, Milleron B., et al. Tumor-derived granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor prolong the survival of neutrophils infiltrating bronchoalveolar subtype pulmonary adenocarcinoma. Am J Pathol 2001; 159: 1423-33.
18. Tazi A, Bouchonnet F, Grandsaigne M., Boumsell L, Hance AJ, Soler P. Evidence that granulocyte macrophage-colony-stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans cells in human lung and lung cancers. J Clin Invest 1993; 91: 566-76.
19. Liu YJ. Thymic stromal lymphopoietin and OX40 ligand pathway in the initiation of dendritic cell-mediated allergic inflammation. J Allergy Clin Immunol 2007; 120: 238-44; quiz 45-6.
20. Voduc KD, Cheang MC, Tyldesley S, Gelmon K., Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010; 28: 1684-91.
21. Lande R, Gregorio J, Facchinetti V., Chatterjee B, Wang YH, Homey B, et al Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007; 449: 564-9.
22. LandeR, Gilliet M. Plasmacytoid dendritic cells: key playersinthe initiation and regulation of immune responses. Ann N Y Acad Sci 2010; 1183: 89-103.
23. Charles J, Chaperot L, Salameire D, DiDomizio J, Aspord C, Gressin R, et al. Plasmacytoid dendritic cells and dermatological disorders: focus on their role in autoimmunity and cancer. Eur J Dermatol 2010; 20: 16-23.
24. Hartmann E, Wollenberg B, Rothenfusser S., Wagner M, Wellisch D, Mack B., et al. Identification and functional analysis of tumor-infiltrating plasma-cytoid dendritic cells in head and neck cancer. Cancer Res 2003; 63: 6478-87.
25. Zou W, Machelon V, Coulomb-L'Hermin A, Borvak J, Nome F, Isaeva T, et al. Stromal-derived factor-1inhuman tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001; 7: 1339-46.
26. Bontkes HJ, Ruizendaal JJ, Kramer D, Meijer C.J., Hooijberg E. Plasmacytoid dendritic cells are present in cervical carcinoma and become activated by human papillomavirus type 16 virus-like particles. Gynecol Oncol 2005; 96: 897-901.
27. Perrot I, Blanchard D, Freymond N., Isaac S, Guibert B, Pacheco Y., et al. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol 2007; 178: 2763-9.
28. Tsuge K, Takeda H, Kawada S., Maeda K, Yamakawa M. Characterization of dendritic cells in differentiated thyroid cancer. J Pathol 2005; 205: 565-76.
29. Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, Guastalla J.P., et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 2004; 10: 7466-74.
30. Vermi W, Bonecchi R, Facchetti F., Bianchi D, Sozzani S, Festa S., et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cellsinprimary cutaneous melanomas. J Pathol 2003; 200: 255-68.
31. +, T cells by plasmacytoid dendritic cells. J Exp Med 2007; 204: 1923-33.
32. Boonstra A, Asselin-Paturel C, Gilliet M., Crain C, Trinchieri G, Liu Y.J., et al. Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential toll-like receptor ligation. J Exp Med 2003; 197: 101-9.
33. Berzofsky JA, Terabe M. Anovel immunoregulatory axis of NKT cell subsets regulating tumor immunity. Cancer Immunol Immunother 2008; 57: 1679-83.
34. DeNardo DG, Barreto JB, Andreu P, Vasquez L., Tawfik D, Kolhatkar N, et al CD4(+)Tcells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009; 16: 91-102.
35. Kobayashi M, Kobayashi H, Pollard R.B., Suzuki F. A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J Immunol 1998; 160: 5869-73.
36. Ciampricotti M, Vrijland K, Hau C.S., Pemovska T., Doornebal CW, Speksnijder EN, et al. Development of metastatic HER2(+) breast cancer is independent of the adaptive immune system. J Pathol 2011; 224: 56-66.
37. Teschendorff AE, Gomez S, Arenas A., El-Ashry D, Schmidt M, Gehrmann M., et al. Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules. BMC Cancer 2010; 10: 604.
38. Pedroza-Gonzalez A., Xu K, Wu T.C., Aspord C., Tindle S, Marches F, et al Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med 2011; 208: 479-90.
39. Wei S, Kryczek I, Zou L., Daniel B, Cheng P, Mottram P., et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res 2005; 65: 5020-6.
40. Matta BM, Castellaneta A, Thomson AW Tolerogenic plasmacytoid DC. Eur J Immunol 2010; 40: 2667-76.
41. Sisirak V, Faget J, Gobert M., Goutagny N, Vey N, Treilleux I., et al. Impaired IFN-a production by Plasmacytoid dendritic cells favors regulatory T cell expansion and contributes to breast cancer progression. Cancer Res 2012; 72:5188-97.
42. Jensen TO, Schmidt H, Moller H.J., Donskov F., Hoyer M, Sjoegren P, et al Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer 2012; 118: 2476-85.
43. Shi Y, Liu CH, Roberts A.I., Das J., Xu G, Ren G, et al Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res 2006; 16: 126-33.
44. Hensley C, Spitzler S, McAlpine B.E., Lynn M., Ansel JC, Solomon AR, et al. In vivo human melanoma cytokine production: inverse correlation of GM-CSF production with tumor depth. Exp Dermatol 1998; 7: 335-41.
45. Zijlmans HJ, Fleuren GJ, Baelde H.J., Eilers PH, Kenter GG, Gorter A. Role of tumor-derived proinflammatory cytokines GM-CSF, TNF-alpha, and IL-12 in the migration and differentiation of antigen-presenting cells in cervical carcinoma. Cancer 2007; 109: 556-65.
46. Trutmann M, Terracciano L, Noppen C., Kloth J, Kaspar M, Peterli R., et al. GM-CSF gene expression and protein production in human colorectal cancer cell lines and clinical tumor specimens. Int J Cancer 1998; 77: 378-85.
47. Su S, Liu Q, Chen J., Chen J, Chen F, He C., et al. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell 2014; 25: 605-20.
48. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995; 13: 399-415.
49. Emens LA, Asquith JM, Leatherman J.M., Kobrin BJ, Petrik S, Laiko M, et al Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 2009; 27: 5911-8.
50. Dranoff G, Jaffee E, Lazenby A., Golumbek P, Levitsky H, Brose K., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993; 90: 3539-43.
51. Tsuchiya Y, Igarashi M, Suzuki R., Kumagai K. Production of colony-stimulating factor by tumor cells and the factor-mediated induction of suppressor cells. J Immunol 1988; 141: 699-708.
52. + T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 1999; 162: 5728-37.
53. Faries MB, Hsueh EC, Ye X, Hoban M., Morton DL. Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin Cancer Res 2009; 15: 7029-35.
54. Filipazzi P, Valenti R, Huber V., Pilla L, Canese P, Iero M., et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007; 25: 2546-53.